Trial Profile
Comparison of the the efficacy and safety of Eculizumab (produced by CinnaGen) with placebo in patients with Paroxysmal Nocturnal Haemoglobinuria
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 19 Jun 2018
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Registrational; Therapeutic Use
- Sponsors CinnaGen
- 19 Jun 2018 New trial record